Cancer Screening Methods for Colorectal and Liver Cancer
(GTI Trial)

Recruiting in Palo Alto (17 mi)

Overseen byShari S Rogal, MD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Pittsburgh

No Placebo Group

Trial Summary

What is the purpose of this trial?Gastrointestinal cancers such as colon cancer and liver cancer cause many deaths in the US. Testing could catch these cancers early, helping people live longer. The goal of this study is to compare two different ways of getting more people tested for these cancers: 1) by directly reaching out to the people who need testing or 2) by helping providers fix issues that hold up testing. The main question it aims to answer is: how should healthcare systems go about choosing one or the other? Researchers will look at cancer testing rates over time at sites that are trying these different approaches. They will also survey and interview participants from these sites.

Eligibility Criteria

This trial is for veterans who may be at risk of gastrointestinal cancers, such as colon or liver cancer. It's designed to find better ways to increase cancer screening rates among this group.

Inclusion Criteria

I am a veteran over 45 with a positive stool test in the last 18 months.

Providers: Healthcare provider or related staff at participating VA site or engaged in CRC or HCC screening pathways in an included VA site (e.g., scheduling)

I am a veteran and 18 years old or older.

+4 more

Exclusion Criteria

Veterans: Limited life expectancy (< 6 months), defined as having a code for hospice

Veterans: Not enrolled in VA

Veterans: No VA encounters in the prior 18 months

+2 more

Participant Groups

The study compares two methods to boost cancer screenings: direct outreach to patients and support for providers to overcome barriers in the testing process. The effectiveness will be measured by changes in screening rates.

2Treatment groups

Active Control

Group I: Patient Navigation (PN)Active Control1 Intervention

Half of the HCC sites and half of the CRC sites will be randomized to PN delivered by Clinical Resource Hub navigators.

Group II: Implementation Facilitation (IF)Active Control1 Intervention

Half of the HCC sites and half of the CRC sites will be randomized to IF delivered by 2 facilitators (one clinical and one evaluation expert) per site.

Implementation Facilitation is already approved in United States for the following indications:

🇺🇸 Approved in United States as Implementation Facilitation for: